Vitamin K antagonist(warfarin) — Competitive Intelligence Brief

Vitamin K antagonist(warfarin) (Vitamin K antagonist(warfarin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K antagonist. Area: Cardiovascular.

marketed Vitamin K antagonist Vitamin K epoxide reductase (VKORC1) Cardiovascular Small molecule

Target snapshot

Vitamin K antagonist(warfarin) (Vitamin K antagonist(warfarin)) — Joon Bum Kim. Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and blood clot formation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vitamin K antagonist(warfarin) TARGET	Vitamin K antagonist(warfarin)	Joon Bum Kim	marketed	Vitamin K antagonist	Vitamin K epoxide reductase (VKORC1)
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Warfarin or coumadin	Warfarin or coumadin	Ottawa Heart Institute Research Corporation	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Nadroparin Calcium and Warfarin	Nadroparin Calcium and Warfarin	Shanghai Zhongshan Hospital	marketed	Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist)	Antithrombin III (nadroparin); Vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Sodium warfarin	Sodium warfarin	University of Padova	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Standard dose oral anticoagulant	Standard dose oral anticoagulant	Korea University Guro Hospital	marketed	Vitamin K antagonist (warfarin-type oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Marevan®	Marevan®	Federal University of São Paulo	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K antagonist class)

1. Joon Bum Kim · 1 drug in this class
2. Population Health Research Institute · 1 drug in this class
3. US Department of Veterans Affairs · 1 drug in this class
4. University Hospital, Bonn · 1 drug in this class
5. University Hospital, Limoges · 1 drug in this class
6. Yunhe Pharmaceutical (Tianjin) Co., Ltd · 1 drug in this class